Psilocybin was first extracted and sold for therapeutic research in 1958 when Albert Hoffman, Sandoz chemist and discoverer of LSD, isolated the active ingredient from Psilocybe Mexicana . Soon after, Sandoz sold synthetic psilocybin under the trade name Indocybin Sandoz for use in psychotherapeutic research. Sandoz ended production in 1965 as the use of LSD and psilocybin became increasingly popular as a recreational drug . Prohibition began in the 1970s when Psilocybin became a schedule 1 compound in 1971 under the UN convention on drugs. Around the same time, Psilocybin was classified as a Schedule I substance under the USA Controlled Substance Act which meant the drug had high potential for abuse, no accepted medical use, and a lack of accepted safety under medical supervision to US regulators. The Schedule I classification made psilocybin illegal to manufacture, distribute, or possess. For these legal reasons, medical research into the clinical uses of psilocybin lost momentum until the 1990s . Interest in psilocybin has recently reignited due to its potential therapeutic capabilities in treating psychological disorders .